Asparlas™ (calaspargase pegol-mknl) – New orphan drug approval
December 20, 2018 - The FDA approved Servier Pharma’s Asparlas (calaspargase pegol-mknl), as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years.
Top